Licensing agreement to develop and commercialize potential treatment for Gaucher
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Protalix (NYSE-Amex: PLX), a leading biopharmaceutical company, in its licensing agreement with Pfizer Inc. to develop and co...
News-Medical-Net,
Fri Dec 04 23:30:20 PST 2009
• Found on Yahoo! News
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Di...
Pfizer and Protalix recently announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in d...
PharmaceuticalOnline,
Wed Dec 02 22:57:34 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News
Pfizer, Protalix enter pact to develop & commercialize Gaucher's disease drug tali...
Pfizer and Protalix have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential ...
PharmaBiz,
Wed Dec 02 21:43:45 PST 2009
• Found on Yahoo! News
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Di...
Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glu...
Medical News Today,
Wed Dec 02 07:15:17 PST 2009
• Found on Yahoo! News
Pfizer Piles Into Biotech With Deal For Gaucher's Drug
Pfizer's move marks the latest push into specialized medicines and puts it on a collision course with Genzyme, maker of a Gaucher's treatment called Cerezyme.
NPR,
Tue Dec 01 07:18:50 PST 2009
• Found on Yahoo! News
Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning
Shares of Protalix BioTherapeutics Inc. dipped 13.7 percent on Tuesday after the biotech unveiled a $115 million profit-sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso (tali...
BioWorld,
Tue Dec 01 18:03:14 PST 2009
• Found on Yahoo! News
Genzyme Ships Gaucher's Treatment From Troubled Allston Plant
Genzyme Corp. (GENZ) has begun shipping vials of Cerezyme, used to treat Gaucher's disease, from its troubled Allston Landing plant. The initial Cerezyme shipments will provide treatment fo...
Nasdaq,
Tue Dec 01 06:48:37 PST 2009
• Found on Yahoo! News
Pfizer To Pay Protalix Up To $115 Million In Gaucher's Deal
Pfizer Inc. (PFE) has reached an agreement to help Protalix Biotherapeutics Inc. (PLX) develop and commercialize a treatment for Gaucher's disease, getting up to $115 million in the process...
Nasdaq,
Tue Dec 01 04:18:34 PST 2009
• Found on Yahoo! News
Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher
Pfizer and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosid...
News-Medical-Net,
Tue Dec 01 04:19:14 PST 2009
• Found on Yahoo! News
Pfizer, Protalix ink deal on technology to make drugs in plant cells, initially fo...
TRENTON, N.J. - Pfizer Inc. will spend up to $115 million for rights to an Israeli biotech company's experimental drug and its promising technology for making that drug and others in carrot...
Minneapolis-St. Paul Star Tribune,
Tue Dec 01 11:22:19 PST 2009
• Found on Yahoo! News
Protalix signs with Pfizer on Gaucher's disease drug
Protalix will make up to $115 million on the deal and retain 40% of future revenues.
Globes Online,
Tue Dec 01 04:11:16 PST 2009
• Found on Yahoo! News
Barclays Capital: $400m potential sales for Protalix drug
Pfizer acquired licensing rights to Protalix's Gaucher's disease drug.
Globes Online,
Thu Dec 03 05:41:23 PST 2009
• Found on Yahoo! News
Pfizer signs development deal with Protalix
Drug developer Pfizer Inc. is paying Protalix BioTherapeutics Inc. $60 million upfront for licensing rights to a developing Gaucher's disease treatment, the companies said on Tuesday.
AP via Yahoo! News,
Tue Dec 01 03:56:03 PST 2009
• Found on Yahoo! News
Pfizer inks deal for new drugmaking technology
Pfizer, Protalix ink deal on technology to make drugs in plant cells, initially for Gaucher's
Newsday,
Tue Dec 01 17:22:50 PST 2009
• Found on Yahoo! News
Pfizer Buys Rights To Protalix Drug for As Much as $115 Million
Pfizer (PFE) unveiled a deal worth up to $115 million Tuesday to acquire the rights to Protalix
Fox News,
Tue Dec 01 06:28:13 PST 2009
• Found on Yahoo! News
Pfizer signs development deal with Protalix
Pfizer signs development deal with Protalix for potential Gaucher's disease drug
Newsday,
Tue Dec 01 04:06:48 PST 2009
• Found on Yahoo! News
Pfizer signs development deal with Protalix
NEW YORK - Drug developer Pfizer Inc. is paying Protalix BioTherapeutics Inc. $60 million up front for licensing rights to a developing Gaucher's disease treatment, the companies said today...
The Philadelphia Inquirer,
Mon Nov 30 23:10:00 PST 2009
• Found on Yahoo! News
Pfizer foots $60M deal to battle rare disease
Pfizer Inc. is paying Protalix BioTherapeutics Inc. for licensing rights to a developing treatment for Gaucher's disease, a low-profile enzyme disorder.
Crain's New York Business,
Tue Dec 01 06:03:50 PST 2009
• Found on Yahoo! News
(AFX UK Focus) 2009-12-01 14:23 UPDATE 2-Pfizer acquires rights to Protalix's Gauc...
(Adds details, background; updates stock movement) Dec 1 (Reuters) - Pfizer Inc said it would acquire the worldwide marketing rights to Protalix BioTherapeutics Inc's experimental drug for ...
Interactive Investor,
Tue Dec 01 06:43:06 PST 2009
• Found on Yahoo! News